Drug Trial Radar · NCT06679270
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 14, 2024
Primary completion
Mar 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Chiesi Farmaceutici S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
Conditions
- Familial Partial Lipodystrophy
Interventions
MetreleptinDrug
Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the Incidence and Frequency of Treatment-Emergent Adverse Events (Safety and Tolerability)Time frame: From enrollment to the end of treatment (until the last participant completes 24 months)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama · Recruiting
Flourish Research
Boca Raton, Florida · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbour, Michigan · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
The Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.